Gambaran Penderita Kanker Payudara Di Bawah Usia 40 Tahun di RSHAM Tahun 2020-2023
DOI:
https://doi.org/10.32734/scripta.v7i1.20789Keywords:
Histopathological, Immunohistochemical, Breast Cancer, IDC, Histopatologi, Imunohistokimia, Kanker PayudaraAbstract
Background: Based on Globocan data in 2020, there were 68,858 new cases of breast cancer, which accounted for about 16.6% of the 396,914 total new cancer cases in Indonesia. The high incidence of breast cancer in Indonesia is not always accompanied by a complete histopathological and immunohistochemical examination. Breast cancer is rare under the age of 40 and women diagnosed with breast cancer under the age of 40 will have a poor prognosis, more aggressive cancer, high malignancy and high mortality rates. Objective: To find out the description of breast cancer patients under the age of 40 at RSHAM in 2020-2023. Method: The research is a descriptive study with a cross sectional design. The sample of this study is breast cancer patients under the age of 40 at RSHAM in 2020-2023 with total sampling technique. Results and Discussion: The results showed that the most common histopathological type is IDC as many as 34 patients (97.1%). The most immunohistochemical sub-type is luminal B as many as 16 patients (45.7%). The highest BMI is normal as many as 27 patients (77.1%). There is no family history of cancer in 35 patients (100%). The most common cancer stage was stage IV with 17 patients (48.6%) and stage IIIB with 14 patients (40%). The most histological grade is histological grade 2 as many as 19 patients (54.3%). Conclusion: The description of breast cancer patients under the age of 40 at RSHAM in 2020-2023 is the IDC histopathological type, luminal B immunohistochemical sub-type, normal BMI, no family history, stage IV, and histological grade 2.
Keywords: Histopathological, Immunohistochemical, Breast Cancer, IDC
Latar belakang: Berdasarkan data Globocan tahun 2020, terdapat 68.858 kasus baru kanker payudara, yang menyumbang sekitar 16,6% dari 396.914 total kasus kanker baru di Indonesia. Tingginya kejadian kanker payudara di Indonesia tidak selalu disertai dengan pemeriksaan histopatologi dan imunohistokimia yang lengkap. Kanker payudara jarang terjadi dibawah 40 tahun, dan jika terjadi lebih agresif dan memiliki prognosis yang buruk. Tujuan: Untuk menggambarkan pasien kanker payudara yang berusia dibawah 40 tahun. Metode: Penelitian ini merupakan penelitian deskriptif dengan desain cross sectional. Sampel penelitian ini adalah pasien kanker payudara dibawah usia 40 tahun di RSHAM tahun 2020-2023 dengan teknik total sampling. Hasil dan Diskusi: Hasil penelitian menunjukkan, jenis histopatologi terbanyak adalah IDC sebanyak 34 pasien (97,1%). Sub tipe imunohistokimia terbanyak adalah luminal B sebanyak 16 pasien (45,7%). IMT terbanyak adalah normal sebanyak 27 pasien (77,1%). Riwayat keluarga menderita kanker tidak ada sebanyak 35 pasien (100%). Stadium kanker terbanyak adalah stadium IV sebanyak 17 pasien (48,6%) dan stadium IIIB sebanyak 14 pasien (40%). Derajat histologi terbanyak adalah derajat histologi 2 sebanyak 19 pasien (54,3%). Kesimpulan. Gambaran penderita kanker payudara dibawah usia 40 tahun di RSHAM tahun 2020-2023 menunjukkan bahwa jenis histopatologi terbanyak adalah IDC dengan sub tipe terbanyak adalah luminal B. Stadium dan derajat histologi terbanyak adalah stadium IV dan derajat 2. Hasil penelitian ini menunjukkan bahwa kanker payudara pada usia dibawah 40 tahun lebih agresif meskipun tidak memiliki riwayat keluarga.
Kata Kunci: Histopatologi, Imunohistokimia, Kanker Payudara, IDC
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Rivan Yudha Rambe, Feby Yanti Harahap, Syamsul Bihar, Yoan Carolina Panggabean

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with SCRIPTA SCORE Scientific Medical Journal agree to the following terms:
- Authors retain copyright and grant SCRIPTA SCORE Scientific Medical Journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in SCRIPTA SCORE Scientific Medical Journal.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in SCRIPTA SCORE Scientific Medical Journal.